文献速递血管炎

靶向CD19的CAR T细胞可防止ANCA诱导的急性肾损伤

CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury.
PubMed 文献 · Ann Rheum Dis · 2024-03-12

该临床前研究在MPO-AAV小鼠模型中验证靶向CD19的CAR T细胞能否清除B细胞(包括产生MPO-ANCA的B细胞)从而防止ANCA诱导的坏死性新月体肾小球肾炎。结果显示CD19 CAR T细胞可迁移并持续存在于骨髓、脾、外周血和肾脏长达8周,清除B细胞和浆母细胞,加速MPO-ANCA下降,并防止坏死性新月体肾小球肾炎。

要点

  • CD19 CAR T细胞而非对照CAR T细胞可清除B细胞和浆母细胞。
  • CD19 CAR T细胞增强MPO-ANCA下降并防止坏死性新月体肾小球肾炎。
  • CD19 CAR T细胞在骨髓、脾、外周血和肾脏持续存在长达8周。

核心结论

  • 这项原理验证研究可能鼓励进一步探索CAR T细胞作为ANCA相关性血管炎患者的治疗手段,以实现无药物缓解。

研究设计与样本

  • 临床前MPO-AAV小鼠模型研究:用鼠源MPO免疫MPO-/-小鼠建立坏死性新月体肾小球肾炎,随后辐照并移植野生型小鼠造血细胞,单独移植或联合CD19 CAR T细胞或对照CAR T细胞。

主要发现

  • CD19 CAR T细胞有效迁移并持续存在于骨髓、脾、外周血和肾脏长达8周。
  • CD19 CAR T细胞而非对照CAR T细胞清除B细胞和浆母细胞,并增强MPO-ANCA下降。
  • CD19 CAR T细胞防止坏死性新月体肾小球肾炎。

临床怎么用

  • 作者认为该原理验证研究可能鼓励进一步探索CAR T细胞作为ANCA相关性血管炎患者的治疗手段,目标是实现无药物缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are life-threatening systemic autoimmune diseases manifesting in the kidneys as necrotizing crescentic glomerulonephritis (NCGN). ANCA antigens are myeloperoxidase (MPO) or proteinase 3. Current treatments include steroids, cytotoxic drugs and B cell-depleting antibodies. The use of chimeric antigen receptor (CAR) T cells in autoimmune diseases is a promising new therapeutic approach. We tested the hypothesis that CAR T cells targeting CD19 deplete B cells, including MPO-ANCA-producing B cells, thereby protecting from ANCA-induced NCGN. METHODS: We tested this hypothesis in a preclinical MPO-AAV mouse model. NCGN was established by immunisation of MPO-/- mice with murine MPO, followed by irradiation and transplantation with haematopoietic cells from wild-type mice alone or together with either CD19-targeting CAR T cells or control CAR T cells. RESULTS: CD19 CAR T cells efficiently migrated to and persisted in bone marrow, spleen, peripheral blood and kidneys for up to 8 weeks. CD19 CAR T cells, but not control CAR T cells, depleted B cells and plasmablasts, enhanced the MPO-ANCA decline, and most importantly protected from NCGN. CONCLUSION: Our proof-of-principle study may encourage further exploration of CAR T cells as a treatment for ANCA-vasculitis patients with the goal of drug-free remission.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Lodka D, Zschummel M, Bunse M, et al. CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury. Ann Rheum Dis. 2024. PMID: 38182404. doi:10.1136/ard-2023-224875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。